RNS Number:4156T
Antisoma PLC
18 December 2003

Not for release, distribution or publication in or into the United States,
Canada, Australia, Republic of Ireland or Japan


                                  ANTISOMA PLC


         SHAREHOLDER APPROVAL FOR COMPLETION OF PLACING AND OPEN OFFER


18 December 2003



Antisoma plc ("Antisoma" or the "Company") announces that at an Extraordinary
General Meeting held earlier today the Resolutions proposed and required to
implement a Placing and Open Offer to raise #15.2 million were duly passed.



On 25 November 2003, the Company announced a Placing and Open Offer of
38,010,941 New Shares at 40 pence per share to raise approximately #15.2 million
(approximately #14.0 million net of expenses).  8,171,103 New Shares were placed
firm with institutional investors and 29,839,838 New Shares were placed with
institutional investors subject to clawback to satisfy valid applications by
Qualifying Shareholders of the Company under the Open Offer.



The Open Offer to Qualifying Shareholders closed at 3.00 pm on 17 December 2003.
Applications were received in respect of 3,676,779 New Shares, including the
159,790 New Shares the Directors of Antisoma agreed to take up under the Open
Offer. These shares, amounting in total to 12.3% of those available under the
Open Offer, were therefore clawed back from the allocations of institutional
investors. The remaining 26,163,059 New Shares and the 8,171,103 New Shares that
were placed firm (constituting a total of 34,334,162 New Shares), will be taken
up by new and existing institutional investors pursuant to the Placing by Nomura
International plc.



Application has been made to the UK Listing Authority for the New Shares to be
admitted to the Official List and to the London Stock Exchange for admission to
trading.  It is expected that dealings in the New Shares will commence at 8.00
am on 19 December 2003, following their admission to the Official List of the UK
Listing Authority and to trading on the market for listed securities of the
London Stock Exchange.  CREST stock accounts are expected to be credited on 19
December 2003 and definitive share certificates in respect of New Shares are
expected to be posted, where applicable, by 29 December 2003.



Commenting, Glyn Edwards, CEO of Antisoma, said, "We're delighted to have
successfully completed a #15.2 million fundraising, enabling us to make
additional investment in the further development of our cancer drug pipeline."



Enquiries:
Antisoma plc                                         Tel: +44 (0)20 8799 8200
Glyn Edwards, Chief Executive Officer
Raymond Spencer, Chief Financial Officer

Nomura International plc                             Tel: +44 (0)20 7521 2000
David Rasouly
John Milad

Financial Dynamics                                   Tel: +44 (0)20 7831 3113
Ben Atwell
Sarah MacLeod



Terms defined in the prospectus issued by Antisoma dated 25 November 2003 shall,
unless the context admits otherwise, have the same meaning in this announcement.



Nomura International plc is acting exclusively for Antisoma in relation to the
Placing and Open Offer and is not advising any other person or treating any
other person as its client in relation thereto, and will not be responsible to
any person other than Antisoma for providing the protections afforded to its
clients nor for providing advice in relation to the Placing, Open Offer or any
other matter referred to in this announcement.



This announcement does not constitute an offer to sell, or the solicitation of
an offer to subscribe for, the New Shares in any jurisdiction in which such
offer or solicitation is unlawful.  The New Shares have not been, and will not
be, registered under the US Securities Act of 1933 (as amended), under the
securities laws of any state of the United States or under the applicable
securities laws of Canada, Australia, the Republic of Ireland or Japan.
Accordingly, unless an exemption under any applicable law is available, the New
Shares may not be offered, sold, transferred, taken up or delivered, directly or
indirectly, in the United States of America, Australia, Canada, the Republic of
Ireland, or Japan or any other country outside the United Kingdom where such
distribution may otherwise lead to a breach of any law or regulatory
requirement.



About Antisoma

Based in London, UK, Antisoma is a biopharmaceutical company that develops novel
products for the treatment of cancer. The Company fills its development pipeline
by acquiring promising new product candidates from internationally recognised
academic or cancer research institutions.  Its core activity is the preclinical
and clinical development of these drug candidates. Antisoma forms partnerships
with pharmaceutical companies to bring its products to market.  In November
2002, Antisoma formed a broad strategic alliance with Roche to develop and
commercialise products from Antisoma's pipeline. Please visit www.antisoma.com
for further information about Antisoma.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

ROIILFEIFLLTLIV